JP2022041802A5 - - Google Patents

Download PDF

Info

Publication number
JP2022041802A5
JP2022041802A5 JP2020187708A JP2020187708A JP2022041802A5 JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5 JP 2020187708 A JP2020187708 A JP 2020187708A JP 2020187708 A JP2020187708 A JP 2020187708A JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5
Authority
JP
Japan
Prior art keywords
antagonist
weeks
administered
pharmaceutical composition
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020187708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022041802A (ja
JP7548784B2 (ja
Filing date
Publication date
Priority claimed from JP2020551453A external-priority patent/JP6799831B1/ja
Application filed filed Critical
Priority to JP2020187708A priority Critical patent/JP7548784B2/ja
Publication of JP2022041802A publication Critical patent/JP2022041802A/ja
Publication of JP2022041802A5 publication Critical patent/JP2022041802A5/ja
Application granted granted Critical
Publication of JP7548784B2 publication Critical patent/JP7548784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020187708A 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物 Active JP7548784B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020551453A JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
PCT/JP2020/032987 WO2022049614A1 (ja) 2020-09-01 2020-09-01 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020551453A Division JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Publications (3)

Publication Number Publication Date
JP2022041802A JP2022041802A (ja) 2022-03-11
JP2022041802A5 true JP2022041802A5 (enExample) 2023-07-26
JP7548784B2 JP7548784B2 (ja) 2024-09-10

Family

ID=73741045

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A Active JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Country Status (10)

Country Link
US (1) US20230391878A1 (enExample)
EP (1) EP4209227A4 (enExample)
JP (2) JP6799831B1 (enExample)
KR (2) KR102269716B1 (enExample)
CN (1) CN116096411A (enExample)
AU (1) AU2020466800A1 (enExample)
CA (1) CA3189847A1 (enExample)
IL (1) IL300694A (enExample)
MX (1) MX2023002482A (enExample)
WO (1) WO2022049614A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CN120441701A (zh) * 2024-02-07 2025-08-08 武汉人福创新药物研发中心有限公司 一种靶向il-31ra的抗体或其抗原结合片段及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2002338476A (ja) * 2001-05-21 2002-11-27 Health Factor Kenkyusho:Kk 腎透析に伴う痒みの予防治療剤
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
CN101589060A (zh) * 2006-01-10 2009-11-25 津莫吉尼蒂克斯公司 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法
EP2749571A3 (en) * 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2548714T3 (es) 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗nr10抗體及其應用
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對il-31拮抗劑之治療的反應之方法
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
KR102156932B1 (ko) * 2017-11-23 2020-09-17 주식회사 헬릭스미스 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물
BR112020021739A2 (pt) * 2018-04-25 2021-01-26 Kiniksa Phamaceuticals, Ltd. tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta

Similar Documents

Publication Publication Date Title
JP2022041802A5 (enExample)
Kuriyama et al. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis
HRP20100014T1 (hr) Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti
TWI738648B (zh) 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
JP2017160178A5 (enExample)
JP2010509369A5 (enExample)
Khan et al. Tramadol use in premature ejaculation: daily versus sporadic treatment
CN111372948A (zh) 用il-17拮抗剂治疗化脓性汗腺炎
JP2020502261A5 (enExample)
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2018515493A5 (enExample)
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20210386712A1 (en) New use of angiotensin ii type 2 receptor agonist
JP2018534259A5 (enExample)
Saco et al. Prurigo nodularis: Picking the right treatment.
WO2013165590A1 (en) Methods for treating idiopathic pulmonary fibrosis
JP2015522077A5 (enExample)
KR20180017145A (ko) 소양증의 치료
JP2023501781A5 (enExample)
KR20230054444A (ko) 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체
JP2023182632A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
AU2015305430A1 (en) Method for treating hyperhidrosis
Lewis et al. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate
Srinivasu et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen
Skoner Montelukast in 2‐to 5‐year‐old children with asthma